©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2021; 13(7): 638-661
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.638
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.638
Systems-level biomarkers identification and drug repositioning in colorectal cancer
Hande Beklen, Esra Yildirim, Medi Kori, Beste Turanli, Kazim Yalcin Arga, Department of Bioengineering, Marmara University, Istanbul 34722, Turkey
Author contributions: Beklen H, Yildirim E, Kori M, Turanli B, Arga KY wrote, revised, and finalized the manuscript and contributed equally.
Supported by TUBITAK (Hande Beklen and Kazim Yalcin Arga) , No. 119S174 ; Marmara University Research Fund (BAPKO) , No. FEN-C-YLP-120619-0199 .
Conflict-of-interest statement: The authors declare no conflict of interests for this article.
Corresponding author: Kazim Yalcin Arga, PhD, Professor, Department of Bioengineering, Marmara University, Goztepe, Istanbul 34722, Turkey. kazim.arga@marmara.edu.tr
Received: March 6, 2021
Peer-review started: March 6, 2021
First decision: April 19, 2021
Revised: April 20, 2021
Accepted: May 25, 2021
Article in press: May 25, 2021
Published online: July 15, 2021
Processing time: 126 Days and 4 Hours
Peer-review started: March 6, 2021
First decision: April 19, 2021
Revised: April 20, 2021
Accepted: May 25, 2021
Article in press: May 25, 2021
Published online: July 15, 2021
Processing time: 126 Days and 4 Hours
Core Tip
Core Tip: Colorectal cancer (CRC) is the most commonly diagnosed cancer in women and men worldwide. Due to the lack of clinical symptoms, it is difficult to diagnose CRC in the early stages. There is an urgent need for alternative, inexpensive and easy-to-measure methods for screening and therapy. Systems biology and drug repositioning (DR) approaches are being used to discover biomarkers and novel targets as well as, existing drugs with different indications to develop new therapeutics and treatment strategies. Our goal was to provide an overview of systems-level biomarkers and insights into DR strategies for the treatment of CRC.